دورية أكاديمية
أعرض في EDS

Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics.

التفاصيل البيبلوغرافية
العنوان: Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics.
المؤلفون: Cysneiros MAPC; Diagnostic and Therapeutic Support Division of Clinical Hospital, Federal University of Goias, Goiania, Brazil., Cirqueira MB; Diagnostic and Therapeutic Support Division of Clinical Hospital, Federal University of Goias, Goiania, Brazil., Barbosa LF; Pathology Department, Federal University of São Paulo, São Paulo, Brazil., Chaves de Oliveira Ê; Surgery Department of Medicine College, Federal University of Goias, Goiania, Brazil., Morais LK; Surgery Department of Medicine College, Federal University of Goias, Goiania, Brazil., Wastowski IJ; Biological Sciences and Health Institute, State University of Goias, Goiania, Brazil., Floriano VG; Clinics Department of Medicine College, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
المصدر: PloS one [PLoS One] 2024 Jul 02; Vol. 19 (7), pp. e0305648. Date of Electronic Publication: 2024 Jul 02 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Pancreatic Neoplasms*/immunology , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/mortality , Adenocarcinoma*/immunology , Adenocarcinoma*/pathology , Tumor Microenvironment*/immunology , B7-H1 Antigen*/metabolism , HLA-G Antigens*/metabolism, Humans ; Male ; Female ; Middle Aged ; Aged ; Programmed Cell Death 1 Ligand 2 Protein/metabolism ; Prognosis ; CD8-Positive T-Lymphocytes/immunology ; Adult ; T-Lymphocytes, Regulatory/immunology ; Aged, 80 and over ; Macrophages/immunology ; Macrophages/metabolism ; Macrophages/pathology
مستخلص: Introduction: Pancreatic adenocarcinoma is an extremely aggressive neoplasm, with many challenges to be overcome in order to achieve a truly effective treatment. It is characterized by a mostly immunosuppressed environment, with dysfunctional immune cells and active immunoinhibitory pathways that favor tumor evasion and progression. Thus, the study and understanding of the tumor microenvironment and the various cells subtypes and their functional capacities are essential to achieve more effective treatments, especially with the use of new immunotherapeutics.
Methods: Seventy cases of pancreatic adenocarcinoma divided into two groups 43 with resectable disease and 27 with unresectable disease were analyzed using immunohistochemical methods regarding the expression of programmed cell death ligand 1 (PD-L1), programmed cell death ligand 2 (PD-L2), and human leukocyte antigen G (HLA-G) molecules as well as the populations of CD4+ and CD8+ T lymphocytes, regulatory T cells (Tregs), and M2 macrophages (MM2). Several statistical tests, including multivariate analyses, were performed to examine how those immune cells and immunoinhibitory molecules impact the evolution and prognosis of pancreatic adenocarcinoma.
Results: CD8+ T lymphocytes and M2 macrophages predominated in the group operated on, and PD-L2 expression predominated in the unresectable group. PD-L2 was associated with T stage, lymph node metastasis, and clinical staging, while in survival analysis, PD-L2 and HLA-G were associated with a shorter survival. In the inoperable cases, Tregs cells, MM2, PD-L1, PD-L2, and HLA-G were positively correlated.
Conclusions: PD-L2 and HLA-G expression correlated with worse survival in the cases studied. Tumor microenvironment was characterized by a tolerant and immunosuppressed pattern, mainly in unresectable lesions, where a broad positive influence was observed between immunoinhibitory cells and immune checkpoint proteins expressed by tumor cells.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Cysneiros et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Onco Targets Ther. 2017 Oct 16;10:5005-5012. (PMID: 29081663)
Am J Blood Res. 2020 Dec 15;10(6):375-385. (PMID: 33489447)
Medicine (Baltimore). 2017 May;96(18):e6369. (PMID: 28471952)
Radiat Oncol. 2019 Aug 8;14(1):141. (PMID: 31395068)
Lancet Oncol. 2016 May;17(5):651-62. (PMID: 27055731)
Ther Adv Med Oncol. 2018 Dec 17;10:1758835918816281. (PMID: 30574212)
Urol Oncol. 2018 Nov;36(11):499.e9-499.e16. (PMID: 30131293)
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167. (PMID: 28619999)
N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407)
Semin Oncol. 2015 Aug;42(4):523-38. (PMID: 26320058)
Onco Targets Ther. 2018 Nov 01;11:7635-7642. (PMID: 30464512)
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. (PMID: 30635425)
Clin Dev Immunol. 2012;2012:656340. (PMID: 22611421)
Crit Rev Clin Lab Sci. 2012 May-Jun;49(3):63-84. (PMID: 22537084)
Front Oncol. 2019 Feb 13;9:47. (PMID: 30891423)
Int J Mol Sci. 2018 Nov 07;19(11):. (PMID: 30405053)
Front Immunol. 2021 Apr 06;12:612271. (PMID: 33889150)
Cancer Res. 2015 Jun 1;75(11):2139-45. (PMID: 25977340)
Pancreatology. 2013 Sep-Oct;13(5):508-16. (PMID: 24075516)
Int J Mol Sci. 2020 Jun 25;21(12):. (PMID: 32630545)
Iran J Immunol. 2018 Mar;15(1):28-37. (PMID: 29549230)
World J Surg. 2010 May;34(5):1059-65. (PMID: 20145927)
J Cancer. 2012;3:285-91. (PMID: 22773932)
Cell Rep. 2017 Jul 18;20(3):558-571. (PMID: 28723561)
Cell Death Dis. 2020 Jul 6;11(7):506. (PMID: 32632098)
Cancers (Basel). 2021 Apr 13;13(8):. (PMID: 33924428)
Clin Cancer Res. 2016 Jul 15;22(14):3606-17. (PMID: 26858311)
Hum Vaccin Immunother. 2016 Mar 3;12(3):563-75. (PMID: 26619245)
Front Oncol. 2020 Dec 23;10:597468. (PMID: 33425752)
Oncoimmunology. 2017 Nov 13;7(2):e1393596. (PMID: 29308326)
Cancer Discov. 2015 Sep;5(9):915-9. (PMID: 26272491)
BMC Cancer. 2017 Sep 5;17(1):618. (PMID: 28870260)
Biochim Biophys Acta. 2015 Jan;1855(1):61-82. (PMID: 25489989)
Int J Mol Sci. 2021 Nov 27;22(23):. (PMID: 34884642)
Cancer Sci. 2011 Jul;102(7):1272-80. (PMID: 21466615)
Cancer Immunol Res. 2017 Jan;5(1):3-8. (PMID: 28052991)
Diagn Pathol. 2018 Jan 17;13(1):5. (PMID: 29378617)
PLoS One. 2014 Sep 05;9(9):e106741. (PMID: 25191901)
J Natl Cancer Inst. 2017 Jan 28;109(6):. (PMID: 28131992)
Oncoimmunology. 2017 Nov 1;7(2):e1390641. (PMID: 29308318)
Front Immunol. 2019 Jun 06;10:1299. (PMID: 31244845)
Proteins. 2017 Nov;85(11):2036-2044. (PMID: 28734034)
Cancer Lett. 2016 Oct 10;381(1):244-51. (PMID: 26723878)
Oncol Lett. 2017 Oct;14(4):4415-4427. (PMID: 29085437)
Front Immunol. 2022 Jan 27;13:796054. (PMID: 35154112)
World J Gastroenterol. 2021 Jul 21;27(27):4298-4321. (PMID: 34366606)
Cancer Med. 2017 Jul;6(7):1614-1626. (PMID: 28602029)
Medicine (Baltimore). 2016 Dec;95(49):e5541. (PMID: 27930550)
Front Immunol. 2018 Sep 27;9:2164. (PMID: 30319626)
J Investig Med. 2012 Apr;60(4):643-63. (PMID: 22406516)
Oncoimmunology. 2018 Nov 20;8(2):e1541535. (PMID: 30713802)
Front Pharmacol. 2019 Feb 28;10:139. (PMID: 30873025)
Sci Rep. 2015 Oct 14;5:15179. (PMID: 26462617)
Arch Pathol Lab Med. 2017 Jun;141(6):851-861. (PMID: 28418281)
Cancer Sci. 2020 Aug;111(8):3057-3070. (PMID: 32495519)
Cancer Discov. 2020 Mar;10(3):422-439. (PMID: 31911451)
Oncogene. 2023 Jun;42(25):2061-2073. (PMID: 37156839)
Asian Pac J Cancer Prev. 2020 May 01;21(5):1495. (PMID: 32458661)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947. (PMID: 31648972)
World J Clin Oncol. 2017 Jun 10;8(3):230-240. (PMID: 28638792)
Ann Gastroenterol Surg. 2018 Jun 22;2(4):274-281. (PMID: 30003190)
Oncotarget. 2016 Aug 2;7(31):50735-50754. (PMID: 27191744)
Transl Oncol. 2020 Oct;13(10):100811. (PMID: 32622310)
Cancer Treat Rev. 2014 May;40(4):513-22. (PMID: 24315741)
Cytokine Growth Factor Rev. 2018 Feb;39:46-61. (PMID: 29373197)
J Immunother Cancer. 2019 Aug 29;7(1):233. (PMID: 31464648)
Cancer Res Treat. 2017 Jan;49(1):246-254. (PMID: 27456947)
Mol Cancer. 2019 Jan 21;18(1):14. (PMID: 30665410)
المشرفين على المادة: 0 (B7-H1 Antigen)
0 (HLA-G Antigens)
0 (CD274 protein, human)
0 (Programmed Cell Death 1 Ligand 2 Protein)
0 (PDCD1LG2 protein, human)
تواريخ الأحداث: Date Created: 20240702 Date Completed: 20240702 Latest Revision: 20240705
رمز التحديث: 20240705
مُعرف محوري في PubMed: PMC11218951
DOI: 10.1371/journal.pone.0305648
PMID: 38954689
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0305648